Group B Streptococcal Colonization among Pregnant Women and Neonates in a Tertiary Care Hospital in South India

Indian J Pediatr. 2022 Dec;89(12):1187-1194. doi: 10.1007/s12098-022-04120-4. Epub 2022 Apr 19.

Abstract

Objectives: To assess the prevalence of maternal and neonatal group B Streptococcal colonization, incidence of neonatal systemic illness, and antibiotic sensitivity of isolates.

Methods: This prospective cohort study was conducted in a South Indian tertiary care hospital. Rectovaginal swabs from pregnant mothers at 360/7-376/7 wk gestation and throat and rectal swabs from their neonates at 48 h of age were collected. Presence of group B Streptococcus (GBS) was identified by broth enrichment step, and traditional microbiologic methods and antibiotic sensitivity of isolates was noted. All mothers received intrapartum antibiotic prophylaxis (IAP). Culture-positive sepsis, clinical sepsis, pneumonia, meningitis, and urinary tract infection were defined as neonatal systemic illness. Neonates of colonized mothers were followed at 3 mo for late-onset sepsis.

Results: Of the 310 mothers, 40 were GBS colonized (prevalence: 12.9%; 95% CI 9.2%, 17.6%). None of the neonates were colonized. Maternal GBS colonization was significantly associated with premature rupture of membrane (RR - 2.93, 95% CI - 1.66-5.16) and neonatal systemic illness (RR - 2.78, 95% CI - 1.39-5.54). Positive correlation was noted between duration of IAP ≤ 4 h and neonatal illness and between maternal GBS colonization and Apgar at 1 min ≤ 4. Clindamycin resistance was noted in 20%. All neonates remained well at 3 mo follow-up.

Conclusion: High maternal colonization alerts the need for GBS screening in India. Clindamycin resistance among GBS isolates questions its effectiveness as alternative therapy in penicillin allergy.

Keywords: Colonization; Group B Streptococcus; Neonatal/Newborn; Pregnant women; Prevalence; Risk factors; Streptococcus agalactiae.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Clindamycin / therapeutic use
  • Female
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control
  • Pregnancy
  • Pregnant Women
  • Prospective Studies
  • Sepsis* / drug therapy
  • Streptococcal Infections* / drug therapy
  • Streptococcal Infections* / epidemiology
  • Streptococcal Infections* / microbiology
  • Streptococcus agalactiae
  • Tertiary Care Centers

Substances

  • Clindamycin
  • Anti-Bacterial Agents